A couple of years ago one of the controversial topics in the Immuno-Oncology space centered around pseudoprogression and whether it was real or not, leading to the development of immune related adverse event (iras) criteria.

Fast forward to Spring 2017 and a new controversy has sprung up, which is focused upon hyperprogression following several publications on the topic.  

It’s a rather nasty situation where people with cancer can rapidly deteriorate and progress faster than normally would be expected.

Is this down to something real associated with the immunotherapy, however, or simply a function of a sick patient taking an inert therapy that takes a while to have an impact?

Strong opinions on the topic have inevitably arose, with different views on whether the phenomenon is real or not and how we could go about assessing and measuring it.  It’s an interesting debate that’s well worth following…

To learn more, subscribers can log-in to read our latest insights or you can gain access to BSB Premium Content.

This content is restricted to subscribers